#MovingMedicineForward: Congratulations to our friends at ProKidney Corp. on their positive interim REGEN-007 Phase 2 data. The trial evaluating ProKidney’s renal autologous cell therapy, rilparencel, in #ChronicKidneyDisease (CKD) patients has demonstrated stabilized #Kidney functions over 18 months, with no rilparencel-related adverse events reported in any study patients. We highlight ProKidney for their commitment to advancing potential #Dialysis prevention & #HealthcareSolutions for individuals with #CKD. Learn more about their research in the article linked below!
CTI Clinical Trial and Consulting Services’ Post
More Relevant Posts
-
#MovingMedicineForward: Congratulations to Poornima Gopalan, CTI’s Clinical Research Associate, for being named the 2024 NGLA Winner in Medical & Healthcare Services! CTI proudly sponsored the 2024 Next Generation Leader Awards (NGLA) hosted by the Northern Kentucky Chamber of Commerce. #ThinkGlobalActLocal: These awards honor individuals active in the community & dedicated to improving the #NKY region!
-
-
#MovingMedicineForward: Explore the latest breakthrough in the International Journal of Spine Surgery's article on Allogeneic Disco Progenitor Cells & Lumbar Disc Degeneration. This study evaluated the safety & efficacy of injectable disc cell therapy. It concluded a high dose of allogeneic disc progenitor cells significantly improved back pain & disc volume one year after a single injection, with results sustained for two years. We highlight these authors for their dedication to #AdvancingHealthcareSolutions for individuals suffering from back pain. Read more about this exciting development below.
Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration--Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial
ijssurgery.com
-
CTI’s #ResearchAssociate (RA) program is committed to #MovingMedicineForward through departmental support, community outreach, & nurturing CTI's future workforce. Our team members advance by participating in departmental trainings, contributing to various projects, & pursuing their career goals. Learn more: https://bit.ly/4ctzXKA #ThinkGlobalActLocal: Currently, 7 #RAs have been promoted globally across 6 departments, supporting 58+ clinical trials, mentoring 85+ students through Adopt A Class, & contributing to 24+ projects beyond clinical trials. They’re also active members of CTI’s #DEIB Committee. #CTICares & we anticipate their continued growth & success at CTI!
-
-
-
-
-
+2
-
-
Check out CTI's latest episode of #MovingMedicineForward – The Podcast! In this episode, we dive into #DiversityInClinicalResearch with insights from CTI’s CEO Timothy Schroeder & Board Member William Fitzsimmons. Hear about Fitzsimmons' journey into #ClinicalResearch, the importance of #Diversity in #ClinicalTrials, & strategies to overcome medical mistrust. We also discuss the latest FDA guidance on diversity & CTI’s initiatives to foster inclusive practices. Subscribe to join our discussion on #AdvancingHealthcareSolutions, clinical research, the patient journey, & more. Listen now at: https://bit.ly/4cv5kEt #CTIPodcast: Don’t forget to share, follow, & subscribe so you never miss an episode!
-
#CTICares: We value work-life balance & family time! Did you know? We proudly offer generous #ParentalLeave benefits to all our employees across the globe. Through our supportive work environment, our #CTIFamily can prioritize work-life balance, allowing us to leave a lasting impact in the #CRO industry to #MoveMedicineForward! Discover how CTI makes a global difference: www.ctifacts.com
-
Happy #IndependenceDay from our #CTIFamily! Today, we celebrate the courage of our founding fathers & honor the sacrifices made for our freedom. Thanks to their bravery, we continue #MovingMedicineForward & #AdvanceHealthcareSolutions.
-
-
#MovingMedicineForward: Congratulations to our friends at Asklepios BioPharmaceutical, Inc. (AskBio) on opening enrollment for REGENERATE-PD, a Phase 2 trial of AB-1005 in Parkinson’s disease. #AskBio, a #GeneTherapy company, has encouraging results from their Phase 1b study & 18-month data, promoting the survival of vulnerable brain cells affected by #Parkinson’s. We highlight AskBio for their commitment to advancing potential #ParkinsonsDisease research! Learn more about their research in the article linked below.
Today we announced the initiation of recruitment to REGENERATE-PD, a Phase 2 clinical study assessing the efficacy and safety of AB-1005, an investigational #genetherapy for the treatment of moderate-stage Parkinson’s disease. More than 10 million people worldwide suffer from Parkinson’s disease, with approximately 1 million living in the United States. #AskBio is dedicated to advancing research and embracing cutting-edge science to explore gene therapy solutions for this debilitating disease. For Medical Media – Read our press release here: https://lnkd.in/g478gFVH #ParkinsonsDisease
-
-
#ThinkGlobalActLocal: For Brain & #AlzheimersAwareness Month, we're raising global awareness & supporting the millions affected by #Alzheimer's disease & other #Dementias worldwide. #CTICares: We’re committed to #MovingMedicineForward, leading the way in #Neurology research. CTI’s Clinical Research Center (CRC) has conducted 16+ trials in this area, including Alzheimer's & Mild Cognitive Impairment. With our expertise in caring for complex & critically ill patients, let's shape the future of #NeurologyResearch together!
-
-
#ThinkGlobalActLocal: We're ready to put #Covington on the global #LifeSciences map! CTI is proud to join the OneNKY Alliance Center, a cutting-edge hub for Covington Life Sciences Partners & ten #NKY growth organizations. We celebrated a major milestone with the Topping Out ceremony, placing the final steel beam. #MovingMedicineForward: Opening Summer 2025, our state-of-the-art wet lab will occupy 15,000 sqft on the 2nd floor, housing several regional #biotech companies. We're excited to contribute to this achievement & move towards a unified #OneNKY!
-
-
#CTICares: Our #Diversity, #Equity, #Inclusion, & #Belonging (DEIB) Council embodies CTI's commitment to recognizing & embracing a multitude of perspectives, backgrounds, & experiences. At CTI, we're dedicated to #MovingMedicineForward & uniting our unique #CTIFamily through our global #DEIB committee. #ThinkGlobalActLocal: Learn how CTI thinks globally & acts locally at https://www.ctifacts.com/
-
